{Reference Type}: Journal Article
{Title}: Evaluating bexicaserin for the treatment of developmental epileptic encephalopathies.
{Author}: Dell'isola GB;Verrotti A;Sciaccaluga M;Roberti R;Parnetti L;Russo E;Costa C;
{Journal}: Expert Opin Pharmacother
{Volume}: 25
{Issue}: 9
{Year}: 2024 Jun 28
{Factor}: 4.103
{DOI}: 10.1080/14656566.2024.2373350
{Abstract}: <B>UNASSIGNED: </B>Developmental epileptic encephalopathies (DEEs) pose significant challenges due to their refractory nature and limited treatment options. Despite advancements in genetic understanding, effective therapies targeting underlying pathophysiology are lacking. Serotoninergic dysfunction has been implicated in epilepsy, sparking interest in serotonin as a therapeutic target.<BR><B>UNASSIGNED: </B>This article explores the potential of bexicaserin, a selective 5-HT2C receptor agonist, as an adjunctive antiseizure medication in DEEs. Bexicaserin is thought to modulate GABAergic neurotransmission, suppressing central hyperexcitability. Preclinical studies demonstrate its efficacy across various seizure models. Clinical trials, including the Pacific Study, reveal promising results in reducing motor seizures. However, challenges such as adverse effects and treatment discontinuation underscore the need for further investigation.<BR><B>UNASSIGNED: </B>The efficacy of 5-HT2C serotoninergic agonists, validated in preclinical and clinical studies, highlights serotonin's role in DEEs. Bexicaserin offers new therapeutic possibilities, potentially synergizing with existing antiseizure medications. Polypharmacotherapy, targeting distinct pathways, may enhance therapeutic outcomes. Monitoring pharmacological interactions and addressing central nervous system comorbidities are crucial for optimizing treatment strategies. Further research is needed to elucidate bexicaserin's mechanisms and potential antiepileptogenic effects.